Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Replidyne's C. difficile solution

Replidyne Inc. last week unveiled REP3123, a MetRS inhibitor in preclinical development that the company thinks will be more effective for severe Clostridium difficile-associated diarrhea than vancomycin.

RDYN thinks REP3123 will have two other advantages over vancomycin: it may reduce CDAD relapses because it reduces the bacterium's sporulation and toxin production, and it should have less effect on beneficial gut flora because

Read the full 629 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers